Metraipolis › archive › dc_08d96084ef02

Emerging venetoclax plus hypomethylating agent-based triplet regimens in newly diagnosed acute myeloid leukemia: updates from the 2025 ASH Annual Meeting — Europe PMC PMID:42509574

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42509574
DOI
10.1186/s40164-[numero omesso]-3
License (as archived)
solo-consultazione
Archived
2026-10-17T16:21:46.012Z
SHA-256 of the archived text
f695e114fcbf76e091432ac3a05e19d935aaff87eca35d4c7405862f93e0313e
Stable URL of this page
https://metraipolis.com/documento/dc_08d96084ef02

How to cite

Emerging venetoclax plus hypomethylating agent-based triplet regimens in newly diagnosed acute myeloid leukemia: updates from the 2025 ASH Annual Meeting — Europe PMC PMID:42509574 — Europe PMC (en), https://europepmc.org/article/MED/42509574 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_08d96084ef02 (Metraipolis archive dc_08d96084ef02, sha256 f695e114fcbf76e091432ac3a05e19d935aaff87eca35d4c7405862f93e0313e)
BibTeX
@misc{dc08d96084ef02,
  title = {Emerging venetoclax plus hypomethylating agent-based triplet regimens in newly diagnosed acute myeloid leukemia: updates from the 2025 ASH Annual Meeting — Europe PMC PMID:42509574},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42509574},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_08d96084ef02; sha256 f695e114fcbf76e091432ac3a05e19d935aaff87eca35d4c7405862f93e0313e},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42509574. Agents can read the archived copy with the MCP tool read_document.